Skip to main content

Table 3 Dropout reason in BC and HNC patients

From: A monocentric, open-label randomized standard-of-care controlled study of XONRID®, a medical device for the prevention and treatment of radiation-induced dermatitis in breast and head and neck cancer patients

Reason for withdrawal BC HNC
SOC (N = 8) Xonrid® + SOC (N = 3) SOC (N = 12) Xonrid® + SOC (N = 6)
Grade > = 3 skin toxicity 4 (50.0%) 1 (33.3%) 5 (41.7%) 6 (100.0%)
Adverse event 1 (12.5%) 1 (33.3%) 1 (8.3%)  
Lost to follow-up 1 (12.5%) 1 (33.3%) 3 (25.0%)  
Consent withdrawal 1 (12.5%)   3 (25.0%)  
Lack of compliance to study treatment or assessment 1 (12.5%)